TOVX Stock Summary and Trading Ideas (Theriva Biologics | AMEX:TOVX)

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Theriva Biologics trades on the AMEX stock market under the symbol TOVX.

As of December 13, 2024, TOVX stock price declined to $1.18 with 49,934 million shares trading.

TOVX has a beta of 1.76, meaning it tends to be more sensitive to market movements. TOVX has a correlation of 0.02 to the broad based SPY ETF.

TOVX has a market cap of $3.28 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that TOVX belongs to (by Net Assets): VXF.

TOVX has underperformed the market in the last year with a price return of -91.6% while the SPY ETF gained +31.7%. TOVX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -67.2% and -11.9%, respectively, while the SPY returned +8.4% and +0.9%, respectively.

TOVX support price is $1.13 and resistance is $1.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TOVX shares will trade within this expected range on the day.